Effects of Solriamfetol on Cognition in Obstructive Sleep Apnea With Excessive Daytime Sleepiness and Impaired Cognition

Hans P. A. Van Dongen, Eileen B. Leary, Graham M.L. Eglit, Christopher Drake, Richard Bogan, Judith Jaeger, Herriot Tabuteau

Conflict of Interest Disclosures for Speakers

SLEEP 2024

To review this speaker's disclosure information, please visit sleepmeeting.org.

SLEEP 2024 Photography Policy

- Photography **IS NOT** permitted during this lecture, except on the Background, Conclusions, and Acknowledgments slides
- Please use the QR code on the Background, Conclusions, or Acknowledgments slides to obtain a PDF of the slides presented

Learning Objectives

Upon completion of this activity, participants should be able to:

- Recognize that some individuals with obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS) have deficits in cognitive functioning
- Understand that solriamfetol treatment led to improvements in overall subjective cognitive function, as measured by the British Columbia Cognitive Complaints Inventory (BC-CCI)
- Know that item analysis of the BC-CCI indicated improvements in cognition in domains that may be related to memory, executive functioning, and processing speed

Background

- Excessive daytime sleepiness (EDS) is common in patients with obstructive sleep apnea (OSA), and can persist in up to 28% of patients despite use of primary airway therapy
- Patients with EDS associated with OSA can have deficits in several cognitive domains
- Solriamfetol (Sunosi®) is a dopamine and norepinephrine reuptake inhibitor with agonistic properties at trace amine–associated receptor 1 (TAAR1) and serotonin 1A receptors
- Solriamfetol is approved in the United States, Canada, and select European countries to treat EDS associated with OSA (37.5–150 mg/day) and narcolepsy (75–150 mg/day)

Bonsignore MR et al, 2021
Gasa M et al, 2013
Pepin JL et al, 2009
Vasudev P et al, 2020
Zhou J et al, 2016
Gursahani H et al, 2022

SHARP Trial (NCT04789174)

- Objective: to assess whether solriamfetol improves cognitive function in patients with EDS associated with OSA and extant impaired cognition
- This **post hoc analysis** evaluated the effects of solriamfetol on individual cognitive complaints and functional items on the **British Columbia Cognitive Complaints Inventory (BC-CCI)**

Scan to Access This Presentation

SHARP Study Design

Phase IV, randomized, double-blind, placebo-controlled, crossover trial



Clinical Visit Structure



British Columbia Cognitive Complaints Inventory (BC-CCI) – Subjective Cognition

SLEEP 2024

6 Cognitive Complaint Items

Participants were asked to rate their **problems with concentration**, **memory**, and **thinking skills** during the past 7 days. Questions included:

1. Forgetfulness/memory problems
2. Poor concentration
3. Trouble expressing thoughts
4. Trouble finding the right word
5. Slow thinking speed
6. Trouble figuring things out or solving problems

A 4-point scale (0–3) was used with higher scores indicating greater cognitive impairment:

0 = Not at all
1 = Some
2 = Quite a bit
3 = Very much

3 Functional Items

Participants were asked to answer questions about how the cognitive complaints impacted their ability to function in the last 7 days. Questions included:

1. Symptoms made it difficult to do job
2. Symptoms made it difficult to have good relationships with family and friends
3. Symptoms made it difficult to enjoy social activities, recreational activities, or hobbies

Answer options included:

False, Not at all True
Slightly True
Mainly True
Very True

Iverson GL et al, 2013

British Columbia Cognitive Complaints Inventory (BC-CCI) – Subjective Cognition

SLEEP 2024

6 Cognitive C

Participants were ask
concentration, mem
the past 7 days. Ques

1. Forgetfulness/
2. Poor concentr
3. Trouble expres
4. Trouble findin
5. Slow thinking
6. Trouble figurir

A 4-point scale (0–3)

indicating greater cog

0 = Not at all
1 = Some
2 = Quite a bit
3 = Very much

Classifications for Cognitive Complaints for the BC-CCI Total Scores

Calculated as the sum of the 6 cognitive complaint responses

- **0 to 4**: “broadly normal”
- **5 to 8**: “mild” cognitive complaints
- **9 to 14**: “moderate” cognitive complaints
- **15 to 18**: “severe” cognitive complaints

onal Items

nswer questions about
ts impacted their ability
. Questions included:

ficult to do job
ficult to have good
ily and friends
ficult to enjoy social
activities, or hobbies

Very True

Iverson GL et al, 2013

Baseline Demographics and Clinical Characteristics

- Of 173 participants screened, 59 were enrolled and had baseline data, 58 had data available for efficacy analyses, and 57 completed the study
- Baseline characteristics, including baseline total British Columbia Cognitive Complaints Inventory (BC-CCI) scores, were generally similar between groups
  - Baseline scores on individual BC-CCI items were generally similar between groups
- Among participants using positive airway pressure, average use was ≥6 hours per night

	Solriamfetol/ placebo (n=30)	Placebo/ solriamfetol (n=29)	Overall (N=59)
Age, mean (SD), years	52.5 (10.5)	51.9 (11.1)	52.2 (10.7)
Sex (female), n (%)	10 (33.3)	11 (37.9)	21 (35.6)
Race, n (%)			
White	24 (80.0)	19 (65.5)	43 (72.9)
Black/African American	4 (13.3)	8 (27.6)	12 (20.3)
Asian	1 (3.3)	2 (6.9)	3 (5.1)
Unknown	1 (3.3)	0	1 (1.7)
Body mass index, mean (SD), kg/m^2	32.8 (4.7)	31.6 (4.0)	32.2 (4.4)
Digit Symbol Substitution Test, age-corrected, mean (SD)	6.6 (1.3)	6.9 (0.8)	6.8 (1.1)
BC-CCI, mean (SD)	**11.4 (2.5)**	**11.4 (2.5)**	**11.4 (2.5)**
Patient Global Impression of Severity (cognitive function), mean (SD)	2.2 (0.8)	2.3 (0.7)	2.3 (0.7)
Epworth Sleepiness Scale total score, mean (SD)	14.8 (2.8)	14.3 (2.7)	14.6 (2.8)
Positive airway pressure use, n (%)	22 (73.3)	20 (69.0)	42 (71.2)
Adherent use (≥4 h/night for 70% of nights), n (%)	18 (60.0)	16 (55.2)	34 (57.6)
Hours of use (among all users), mean (SD)	6.0 (2.4)	6.6 (2.7)	6.3 (2.5)

Study Findings: Primary Findings and Safety

Primary Efficacy Endpoint

Solriamfetol significantly improved objective cognitive function compared with placebo as measured by the Coding subtest (comparable to the Digit Symbol Substitution Test) of the Repeatable Battery for the Assessment of Neuropsychological Status



Safety

- All treatment-emergent adverse events (TEAEs) were mild or moderate in severity
- There were no deaths, serious TEAEs, or TEAEs that led to discontinuation of the study

n (%)	Solriamfetol (n=58)	Placebo (n=58)
Any TEAE	11 (19)	6 (10)
Nausea	4 (7)	1 (2)
Anxiety	2 (3)	0
Insomnia	1 (2)	1 (2)
Nasopharyngitis	1 (2)	1 (2)

Common TEAEs (reported by ≥2 participants)

Study Findings: Overall Improvement in Subjective Cognitive Function

Overall, British Columbia Cognitive Complaints Inventory (BC-CCI) scores showed greater reduction from baseline (ie, more improvement in subjective cognitive function) after solriamfetol treatment compared with placebo



Solriamfetol significantly improved subjective cognitive function compared with placebo

Least squares mean difference: −1.58
(95% CI: −2.53, −0.63)

Cohen's *d*: 0.45

Study Findings: Cognitive Complaint Items



Conclusions

- Consistent with previous reports showing improvement on objective cognitive measures, solriamfetol led to significant subjective improvements overall, and particularly in subjective cognitive domains that may be related to **memory**, **executive functioning**, and **processing speed**

- Solriamfetol has the potential to improve subjective cognitive functioning in participants with impaired cognition associated with OSA and EDS

- Please come to see our poster #390 at 11:00-11:45 on Wednesday

Scan to Access This Presentation

Acknowledgements

- The authors thank the participants who contributed data, personnel who collected data, and consultants who contributed to the design of the SHARP Study.
- This study was sponsored by Axsome Therapeutics and Jazz Pharmaceuticals

- Please come to see our poster #390 at 11:00-11:45 on Wednesday

Scan to Access This Presentation

Backup Slides

Baseline Scores on Individual British Columbia Cognitive Complaints Inventory (BC-CCI) Items

SLEEP 2024

Baseline scores on individual BC-CCI items were generally similar for participants randomized to solriamfetol/placebo versus placebo/solriamfetol

	Mean (SD)	Solriamfetol/placebo (n=29)	Placebo/solriamfetol (n=29)	Overall (N=58)
Cognitive complaint items	Forgetfulness/memory problems	1.93 (0.70)	2.00 (0.71)	1.97 (0.70)
	Poor concentration	2.10 (0.86)	2.21 (0.68)	2.16 (0.77)
	Trouble expressing thoughts	1.93 (0.80)	1.76 (0.74)	1.84 (0.77)
	Trouble finding the right word	1.97 (0.82)	1.79 (0.56)	1.88 (0.70)
	Slow thinking speed	1.93 (0.75)	1.93 (0.80)	1.93 (0.77)
	Trouble figuring things out	1.62 (0.73)	1.76 (0.64)	1.69 (0.68)
Functional items	Vocational functioning	1.97 (1.05)	1.83 (0.97)	1.90 (1.00)
	Family/friends functioning	1.52 (1.02)	1.72 (1.16)	1.62 (1.09)
	Social/recreational functioning	1.66 (1.11)	1.66 (1.04)	1.66 (1.07)

Study Findings: Functional Items



There were no significant improvements on functional items with solriamfetol compared with placebo